AST Newsletter Archives

The CLSI AST Outreach Working Group (ORWG) is part of the CLSI Subcommittee on Antimicrobial Susceptibility Testing (AST) and was established in 2015. The formation of the working group originated in a desire to efficiently convey information regarding contemporary AST practices, recommendations, and resources to the clinical microbiology community.

Sign-up For the AST News Update E-mails

Archived Newsletters:

  • Volume 1, Issue 1 Spring 2016
    • About CLSI AST ORWG
    • CLSI AST Subcommittee and Meetings
    • Availability of CLSI AST Subcommittee Materials
    • Recently Published CLSI AST Documents
    • Educational Materials for Carbapenem-resistant Enterobacteriaceae (CRE)
  • Volume 1, Issue 2 Winter 2016
    • Do You Need Help With Verification of Your AST System?
    • Special Considerations for Susceptibility Testing of Streptococcus agalactiae (Group B Streptococcus)
    • Continuing Conversation About Colistin!
    • The CLSI Anaerobe Working Group and Anaerobe Susceptibility Testing
    • Resistance Hot Topic! Vancomycin-Variable Enterococci:
      An Unrecognized Threat?
  • Volume 2, Issue 1 Spring 2017 (English)
    • The One Health Initiative
    • What is the Antibiotic Resistance Laboratory Network (ARLN)
    • A New Phenotypic Test for Detection of Carbapenemases – The Modified Carbapenem Inactivation Method (mCIM)
    • Carbapenems and Enterobacteriaceae: What is the difference between CRE vs Carbapenemase-Producing (CP)-CRE vs nonCP-CRE?
    • Newer Developments in Antifungal Susceptibility Testing - Species-Specific Breakpoints for Candida spp.
    • The 21st Century Cures Act and the Future of AST
    • Hot Topic – OXA Carbapenemases
    • In Memoriam – Dr. Paul Schreckenberger
  • Boletín de AST noticias de Junio 2017 (Español) 
    • La iniciativa One Health
    • ¿Que es la Antibiotic Resistance Laboratory Network (ARLN)?
    • Un nuevo test fenotípico para la detección de Carbapenemasas - The Modified Carbapenem Inactivation Method (mCIM)
    • Carbapenems y Enterobacteriaceae: Cual es la diferencia entre CRE vs productores de carbapanemasa (CP)- ¿CRE vs no-CP-CRE?
    • Nuevos desarrollos en pruebas de susceptibilidad antifúngica – Puntos de corte específicos para especies de Candida spp.
    • 10 El acta de curas para el sigo 21 y el futuro de AST
    • Tema Candente – Carbapenemasas OXA
    • En memoria – Dr. Paul Schreckenberger
  • Volume 3, Issue 1 Winter 2018 (English)
    • 21st Century Cures Act: Exciting News
    • Feature Article: Understanding Pharmacokinetics (PK) and Pharmacodynamics (PD)
    • Case Study: Direct Detection of MRSA/MSSA from Positive Blood Cultures
    • Burning Question: When Should Clinical Microbiology Laboratories Perform Carbapenemase Detection Tests
    • Article: Respiratory Illnesses and the Need for Antibiotic Stewardship
    • Article: Antimicrobial Susceptibility Testing of Bacteria Associated with Community-Acquired Pneumonia
    • Hot Topic: Candida auris
  • Volume 3, Issue 1 Winter 2018 (Chinese)
    • 21世纪治愈法案(The 21st Century Cures Act)——令人振奋的新闻
    • 专题文章:理解药代动力学(PK)和药效学 (PD)
    • 病例研究:血培养阳性样本直接检测 MRSA/MSSA
    • 最关注的问题:临床实验室应该何时进行 碳青霉烯酶检测试验?
    • 呼吸系统疾病和抗生素管理的需求
    • 社区获得性肺炎相关细菌的抗微生物药物 敏感试验
    • 热点话题——耳念珠菌
  • Volume 3, Issue 2 Spring 2018 (English)
    • Featured Article: Part 1 New β-lactam combination agents for the treatment of Gram-negative bacterial infections: what the clinical microbiologist needs to know!
    • Featured Article: Part 2 Why all the fuss over quality control of β-lactam combination agents?
    • Case Study: Cefazolin, Urine, and Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis: Entertaining Solutions for Antimicrobial Susceptibility Testing and Reporting
    • Burning Question: What Should Clinical Laboratorians Know About Gonorrhea in 2018?
    • Hot Topic: It’s Enough to mec You Crazy!
  • Volume 4, Issue 1 - January 2019 (English)
    • Featured Article: Applying Fluoroquinolone Pharmacokinetics, Pharmacodynamics, and Updated Clinical Breakpoints for Gram-Negative Pathogens to Determine Optimal Dosing
    • Case Study: Digging Deeper into Understanding Cefazolin Reporting for Enterobacteriaceae
    • Practical Tips: #1 When Should Antifungal Susceptibility Testing be Performed for Candida species Isolated from Clinical Specimens?
    • Practical Tips: #2 Differences in Disk Content Recommended by CLSI and EUCAST for Disk Diffusion Testing
    • Hot Topic: The Cefazolin Inoculum Effect for MSSA
    • Quality Corner: Antimicrobial Susceptibility Testing Quality Control of β-lactam/β-lactamase Inhibitor Combination Agents in Clinical Development
  • Volume 4, Issue 1 - January 2019 (Chinese)
    • 专题文章: 应用氟喹诺酮类药物的药代动力学、药效学和 更新的革兰阴性菌临床折点来确定最佳剂量
    • 病例研究: 深入了解肠杆菌科头孢唑林的报告
    • 实用技巧: #1 对分离自临床标本的念珠菌,何时应该做 抗真菌药物敏感性试验?
    • 实用技巧:#2 CLSI和EUCAST推荐的纸片扩散法中(药物) 纸片含量的差异
    • 热点: 头孢唑啉对MSSA的接种效应
    • 质量角: 临床研究中的β 内酰胺类/β 内酰胺酶抑制剂 复合制剂的抗微生物药物敏感试验的质量控 制
  • Volume 4, Issue 2 - June 2019 (English)
    • Future CLSI Meetings
    • New/Updated Documents
    • New Information on M100
    • Featured Article: Practical Approach to Evaluating Requests to Test New Antimicrobials
    • Practical Tips: Where Can We Find the Latest Resources for Candida auris?
    • Hot Topic: The Antibiotic Resistance Laboratory Network (AR Lab Network) – Bridging the Gap by Offering Expanded Antimicrobial Susceptibility Testing
    • In Memoriam: Sydney M. Finegold, MD